The control of body weight and of blood glucose concentrations depends on the exquisite coordination of the function of several organs and tissues, in particular the liver, muscle and fat. These organs and tissues have major roles in the use and storage of nutrients in the form of glycogen or triglycerides and in the release of glucose or free fatty acids into the blood, in periods of metabolic needs. These mechanisms are tightly regulated by hormonal and nervous signals, which are generated by specialized cells that detect variations in blood glucose or lipid concentrations. The hormones insulin and glucagon not only regulate glycemic levels through their action on these organs and the sympathetic and parasympathetic branches of the autonomic nervous system, which are activated by glucose or lipid sensors, but also modulate pancreatic hormone secretion and liver, muscle and fat glucose and lipid metabolism. Other signaling molecules, such as the adipocyte hormones leptin and adiponectin, have circulating plasma concentrations that reflect the level of fat stored in adipocytes. These signals are integrated at the level of the hypothalamus by the melanocortin pathway, which produces orexigenic and anorexigenic neuropeptides to control feeding behavior, energy expenditure and glucose homeostasis. Work from several laboratories, including ours, has explored the physiological role of glucose as a signal that regulates these homeostatic processes and has tested the hypothesis that the mechanism of glucose sensing that controls insulin secretion by the pancreatic beta-cells is also used by other cell types. I discuss here evidence for these mechanisms, how they integrate signals from other nutrients such as lipids and how their deregulation may initiate metabolic diseases.
Introduction
Glucose can be used by all cells of the body as a source of metabolic energy and in diverse biosynthetic reactions. The brain has, however, a unique dependence on glucose for ATP production and hypoglycemia is a major threat for its functioning and, thus, for survival. Therefore, several mechanisms have evolved to closely monitor glucose, from the time it is ingested to its absorption in the gut and its increase or decrease in blood concentration. In the mouth, glucose receptors trigger a nervous reflex that stimulates the cephalic phase of insulin secretion. In the gut, glucose absorption triggers the secretion of the glucoincretin hormones GIP and GLP-1, and its absorption through the intestinal epithelium activates glucose-sensing nerve terminals present in the intestinal wall. When collected in the portal vein, glucose activates glucose sensors involved in the control of vagal afferents that inform the hypothalamus, through nervous relay in the brainstem, of the incoming glucose. This triggers several adaptive response needed to prepare the organism to dispose of glucose and to terminate feeding.
In the liver, glucose is stored as glycogen or is catabolized for ATP generation or for conversion to fatty acids. Glucose can also trigger several transcriptional events to activate its own catabolism, in particular it activates the transcription factor carbohydrate responsive element binding protein, 1 which induces the expression of not only L-pyruvate kinase but also acetyl-CoA carboxylase and fatty acid synthase, two enzymes that catalyze lipogenesis from glucose-derived metabolites. Glucose regulates pancreatic hormone secretion, that is, insulin and glucagon in an opposite manner. Although glucose triggers insulin secretion through its metabolism by beta-cells, the regulation of glucagon secretion is more complex and depends on several control mechanisms. Pancreatic alpha-cells have an intrinsic capacity to monitor glucose levels but are also under the control of insulin secretion by the beta-cells, which inhibits glucagon secretion. There is also ample evidence that the alpha-cell secretory activity is strongly regulated by both the sympathetic and parasympathetic nervous systems and the sympathoadrenal axis, implying that glucose and hypoglycemiadetecting cells control the activity of the autonomic nervous system. The identity of these cells is not yet firmly established, but evidence indicates that they are present at multiple anatomic sites and that the information they monitor is integrated centrally to control efferent signals to the alpha-cells. The same or perhaps separate glucosesensing cells also control feeding behavior and energy expenditure by regulating the melanocortin pathway, where the glucose signal is integrated with that of various hormones and nutrients to control energy homeostasis.
The sites of glucose detection and how they are connected to each other to control glucose and energy homeostasis have received much attention over recent years, using a combination of classical techniques to monitor the activation of glucose-responsive neurons, and the study of genetically modified mice to evaluate the role of specific genes in glucose sensing and their role in integrated physiology.
Here, I will review studies indicating that impaired glucose sensing not only leads to a defect in insulin secretion but also to abnormally high glucagon levels in the fed state and to a defect in feeding control. Importantly, many of the studies leading to these observations were gained using mice with defects in single genes involved in glucose sensing in pancreatic beta-cells. These data therefore support the notion that the beta-cell paradigm for glucose sensing may apply to other glucose-sensing cells, although important differences exist. The deregulation of these sensing systems leads to several defects associated with obesity and type 2 diabetes, such as uncontrolled food intake, abnormal glucagon secretion in the fed state and a defect in first-phase insulin secretion. These data therefore support a defect in glucose sensing as a possible initiator of obesity and type 2 diabetes.
Sites and mechanisms of glucose sensing
Pancreatic beta-and alpha-cells Glucose sensing by pancreatic beta-cells is a unique signaling process in which increases in extracellular glucose are immediately translated into proportional depolarization of the plasma membrane. Key in this process is the increase in the ATP/ADP ratio, after glucose metabolism that leads to the closure of K ATP channels. Voltage-dependent Ca 2 þ channels are then activated and the influx of Ca 2 þ triggers insulin secretion. The typical dose-response curve of glucosestimulated secretion by beta-cells is controlled by the particular kinetic property of glucokinase (K m B8 mM). 2 In rodents, the glucose uptake step is controlled by the glucose transporter GLUT2, which allows the unrestricted access of glucose to glucokinase and has therefore only a permissive role in glucose signaling. 3 Many studies have therefore evaluated the role of the K ATP channel, an hetero-octamer formed of four Kir6.2 and four SUR1 subunits, 4 of glucokinase and of GLUT2, in glucose sensing by beta-cells and cells controlling the activity of peripheral and central neurons.
Pancreatic alpha-cells have also been reported to be glucose sensitive, with increases in glycemia-inhibiting and hypoglycemia-stimulating glucagon secretion. Alpha-cells express the K ATP channel and glucokinase, but not GLUT2, and are therefore endowed with at least two critical regulators of glucose sensing.
The hepatoportal vein glucose sensor After its absorption through the intestinal epithelium, glucose is collected in the hepatoportal vein, where it activates a glucose-sensing system that decreases the firing activity of vagal afferents that project to the nucleus of the tractus solitarius and the lateral and paraventricular hypothalamus. 5 The mechanism of glucose detection by the hepatoportal sensor was shown to require the presence of GLUT2, 6 and possibly glucokinase. 7 Furthermore, its activation by portal glucose infusion was found to be inhibited by somatostatin 8 and to be modulated by GLP-1. [9] [10] [11] The cells involved in this sensing mechanism are however not yet identified. They may either be neurons whose nerve endings are present below the endothelial cell layer or the glomuslike cells associated with the portal vein, which are richly innervated by vagal afferents. 12 In addition, there is evidence that there may be more than one type of glucose-sensing cells, in particular, as glucose decreases the firing rate of hepatic vagal afferents, 13 whereas GLP-1, which is required for normal glucose sensing, increases it. 14 In addition, in contrast to beta-cell glucose sensing, the portal vein sensor can be activated by pyruvate and lactate. 15 The hepatoportal sensor has been shown to control multiple physiological function. 5 Its activation stimulates first-phase insulin secretion, 16, 17 increases hepatic glucose clearance, 18 stimulates, in an insulin-independent manner, peripheral tissue glucose uptake, 8, 19 suppresses glucagon secretion (see below) and terminates feeding. 20, 21 Thus, the combination of physiological as well as pharmacological and genetic studies has provided strong evidence for an important role of the hepatoportal sensor in the regulation of several homeostatic functions. These studies indicate that glucose sensing in the portal vein not only shares similarity with that of the pancreatic beta-cell but also has differences, particularly the capacity to be activated by pyruvate and lactate.
Brain glucose sensing: glucose-excited and glucose-inhibited neurons in the hypothalamus and the brainstem Changes in blood glucose levels can be monitored by neuronal cells located in the hypothalamus or the brainstem. Two types of glucose-responsive neurons have been described: glucose-excited (GE) neurons, whose firing rate is increased by elevation in extracellular glucose concentration, and glucose-inhibited (GI) neurons, which are activated when glucose concentrations decreases. 22 These two types of neurons are differentially expressed in different hypothalamic areas with GI neurons being most abundant in the lateral hypothalamus (LH) and GE neurons more abundant in the ventromedial hypothalamus (VMH). 23 Glucose-modulated neurons are however also found in the arcuate nucleus (AN), the paraventricular hypothalamus (PVN) and the dorsomedial hypothalamus. It has been suggested that activation of the firing rate of GE neurons depends on the closure of the K ATP channel by increases in extracellular glucose, whereas GI neurons may increase their firing rate in response to hypoglycemia after inactivation of the Na/K ATPase. 23 Activity of these GE and GI neurons may be modulated by leptin. This has been described, for instance, for the NPY-containing neurons of the AN. 24 Recently, the presence in the AN of GE and GI neurons responsive to glucose over either a low (0-5 mM) or a high glucose concentration range (5-20 mM) has been described, the latter are referred to as HGE (high glucose-excited) or HGI (high glucose-inhibited) neurons, respectively. 25, 26 GE and GI neurons are also present in the brainstem, in particular in the area postrema, the nucleus of solitary tract (NTS), the dorsal motor nucleus of the vagus and the basolateral medulla in regions containing A1 and C1 neurons. [27] [28] [29] [30] [31] [32] The NTS is a structure that integrates internal signals and transmits them to the hypothalamus. Neurons in the NTS and the basolateral medulla are sensitive to small variations in glycemia and may regulate the activity of hypothalamic neurons, in particular those from the lateral hypothalamus and the VMH, with which they are synaptically connected. Below I will discuss how these different glucose sensors integrate their function to control counter-regulation and feeding behavior and how lipid and glucose metabolism interact to modulate the function of these sensors.
Counter-regulation
A decrease in blood glucose concentration below the euglycemic level triggers an immediate secretion of glucagon, which triggers hepatic glycogenolysis and the release of glucose into the blood. This response is strengthened by the secretion of epinephrine through activation of the sympathoadrenal system and of glucocorticoids and growth hormone, which together also leads to long-term responses including the transcriptional activation of gluconeogenic genes.
The pancreatic alpha-cells have been reported to directly sense and respond to a decrease in extracellular glucose level by an increased secretion of glucagon. 33 This has recently been challenged using purified alpha-cell populations, which, in contrast, were reported to increase their secretory activity with increase in extracellular glucose concentrations. 34 The exact contribution of direct glucose sensing by alpha-cells in the physiological control of glucagon secretion remains uncertain. 35 Insulin has been proposed to be a physiological regulator of glucagon secretion. 36 However, glucagon secretion increases markedly only when glucose decreases below euglycemic levels, that is, when insulin secretion is at the basal rate. Thus, increases in insulin secretion can only play a role in suppressing glucagon secretion and not in stimulating it at low glucose concentrations. There is strong evidence that both the sympathetic and parasympathetic branches of the autonomic nervous system, as well as the sympathoadrenal axis, control alpha-cell secretion and that this nervous control may be the more physiologically important one, both in rodents and in humans. 37, 38 The important question is then to identify the glucose-sensing cells that activate the autonomic response leading to glucagon secretion, for two reasons. Firstly, in type 1 diabetes, there is a progressive impairment of the counter-regulatory response, which deteriorates after each hypoglycemic episode, leading to hypoglycemiaassociated autonomic failure. Insulin-induced hypoglycemia is thus a major risk associated with the treatment of type 1 diabetes. 39 Secondly, in type 2 diabetic patients, a defective suppression of glucagon secretion after meal absorption worsens postprandial hyperglycemia. 40 Hypoglycemia can be detected at multiple sites to trigger glucagon secretion. These sites include the portal vein area, the brainstem and the hypothalamus. Initial studies showed that glucagon plasma levels that are increased by insulininduced hypoglycemia could be suppressed by the stimulation of the hepatoportal vein glucose sensor by portal glucose infusion. [41] [42] [43] [44] In contrast, the activation of glucagon secretion by insulin-induced hypoglycemia was not inhibited by inactivating the hepatic vagal nerve, suggesting that this sensor did not participate in the induction of counterregulation. [45] [46] [47] However, more recent data showed that celiac-superior mesenteric ganglionectomy, but not vagotomy, suppressed the response to insulin-induced hypoglycemia, suggesting that the hepatoportal sensor may indeed participate in triggering glucagon secretion. 48, 49 In the central nervous system, sites of glucose detection for the control of counter-regulation are present in the hypothalamus and different brainstem nuclei. In the hypothalamus, lesion studies as well as pharmacological and genetic interferences with glucose detection systems have provided evidence for an important role of the VMH in the control of glucagon secretion. 50 For instance, glucagon secretion can be induced by the direct injection of 2-deoxy-Dglucose (2-DG) in the VMH 51 or, in contrast, hypoglycemiainduced glucagon secretion can be suppressed by the direct VMH injection of glucose. 52 The involvement of brainstem nuclei in the control of glucagon secretion has been evidenced by experiments in Glucose sensing in metabolic diseases B Thorens which 5-thio-glucose induced a counter-regulatory response only when injected in the fourth but not in the third ventricle 53 when the cerebral aqueduct, which allows the circulation of cerebrospinal fluid between the third and fourth ventricle, was obstructed. In addition, injections of 5-thio-glucose in different hypothalamic nuclei failed to induce a glucoregulatory response, whereas its injection into the NTS and the basolateral medulla region containing the A1/C1 catecholaminergic neurons, which project to different sites of the hypothalamus, induced a strong response. [54] [55] [56] Also, in decerebrated rats, the hyperglycemic response to an intraperitoneal injection of 2-DG is preserved, 57 and c-fos immunostaining revealed that the activated neurons are present in the NTS, the dorsal motor nucleus of the vagus and the catecholaminergic neurons of the basolateral medulla. 58 Thus, hypoglycemia can be detected at several sites, the hepatoportal vein area, the brainstem and the hypothalamus. Although not discussed here, there is evidence that glomus cells in the carotid body are also activated by hypoglycemia and may contribute to the overall control of counter-regulation. 59, 60 The role of Glut2, glucokinase and the K ATP channel in the control of glucagon secretion has been investigated in several studies. Mice with inactivation of the Glut2 gene, and that express a transgenic glucose transporter in their pancreatic beta-cells to preserve normal glucose-stimulated insulin secretion (ripglut1;glut2 À/À mice), 61 display plasma glucagon levels in the fed state that are abnormally high. As glucagonemia can be rapidly normalized by ganglionic blockade, 62 this indicates that Glut2 (which is not expressed in alpha-cells) is required for the control of glucagon secretion. This was further shown by the lack of stimulation or decrease in plasma glucagon during, respectively, hypoglycemic or hyperinsulinemic clamp experiments. This can be not only due to the role of Glut2 in hepatoportal glucodetection but also due to a role in central glucodetection, as this transporter is also expressed in the hypothalamus and the brainstem. 63 A role in central glucose sensing was indeed evidenced by the failure of intracerebroventricular 2-DG injections to stimulate glucagon secretion in these mutant mice. 64 Furthermore, the analysis of c-fospositive cells in response to intraperitoneal 2-DG injections indicated a decreased number of activated cells in the brainstem, in particular in the NTS and the dorsal motor nucleus of the vagus in the Glut2-null mice. At the level of the hypothalamus, a reduced stimulation of c-fos-positive cells was observed in the PVN but not in the VMH. Thus, Glut2-dependent glucose sensors are also located centrally where they are involved in the control of counter-regulation. Interestingly, however, the VMH c-fos response to 2-DG injection was independent of Glut2 expression, indicating that several central nuclei detect glucose by different mechanisms to control glucagon secretion. To determine whether Glut2 needs to be expressed in neurons or astrocytes for the control of counter-regulation, Glut2 was expressed by transgenesis in the ripglut1;glut2 À/À mice under the control of the glial acidic fibrillary protein (glial-specific) or the synapsin (neuron-specific) promoter. Glucagon secretion in response to hypoglycemic clamps or after intracerebroventricular 2-DG injections, as well as a normal pattern of c-fos activation in the brainstem, were restored only when Glut2 was expressed in astrocytes. 64 This suggests that, glucose sensing for the control of counterregulation was dependent on a metabolic coupling between neurons and astrocytes. A role for hypothalamic glucokinase in glucagon secretion was also shown 65, 66 as well as the involvement of the K ATP channel. For instance, intracerebroventricular or direct VMH injection of the K ATP channel inhibitor glibenclamide blocked the counter-regulatory response to a hypoglycemic clamp. 67 Inactivation of K ATP channel by Kir6.2 gene knockout also leads to impaired glucagon response, and this was correlated with suppressed glucose-regulated firing activity of VMH neurons. 68 In contrast, the activation of ATPsensitive K þ channels in the VMH amplifies counterregulatory hormone responses to hypoglycemia in normal and recurrently hypoglycemic rats. 69 Although the above studies indicate that Glut2, glucokinase and the K ATP channel are required for central glucose sensing and counter-regulation, it is not yet clear if these different proteins need to be present in the same cells for normal glucose sensing. The K ATP channel has a very broad distribution in the brain and it is unlikely that it has a function in glucose sensing in all the cells in which it is expressed. Glucokinase and Glut2 have much more restricted distribution and have only partially overlapping sites of expression. For instance, glucokinase is expressed at high level in the hypothalamus and at a low level in the brainstem, whereas Glut2 is expressed at low level in both sites.
Feeding control
The regulation of feeding behavior is an extremely complex system, in which the melanocortin neuronal circuit of the hypothalamus plays a pivotal role. Indeed, it integrates hormonal (ghrelin, insulin, PYY3-36, and so on), nutrient (glucose, lipids) and nervous signals triggered by food ingestion and absorption through the gastrointestinal tract, and also signals derived from fat (leptin, adiponectin) to inform about the levels of stored energy. 70 Glucose was postulated a long time ago to play a specific role in the regulation of feeding, 71, 72 and it was shown that initiation of feeding is usually preceded by a decrease in glycemia level, 73 which, if prevented by glucose infusion, suppresses feeding. 74 On the other hand, the induction of cellular glucoprivation by intraperitoneal or intracerebroventricular administration of the glucose anti-metabolite 2-DG is a strong signal to induce food intake.
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A possible role of the hepatoportal vein sensor in the glucose regulation of feeding was proposed in initial studies by Russek, 20, 21 who showed that intraperitoneal glucose injection in the rat rapidly decreased feeding, an effect attributed to glucose inducing a satiety signal after being collected in the portal vein. In addition, portal vein infusion of glucose inhibits, 78 whereas 2-DG stimulates 75 feeding and intrameal portal glucose infusion increases satiation in the rat. 79 The hindbrain is also a major site where glucoprivation, induced by intracerebroventricular 2-DG injections, is detected to trigger feeding. Indeed, direct injection of this anti-metabolite into the lateral hypothalamus or the VMH, 77 or injection into the lateral ventricles but in the presence of an obstruction of the cerebral aqueduct, 53 failed to activate feeding. Furthermore, food intake can be stimulated by direct injections of 5-thio-glucose into the basolateral medulla, the dorsal motor nucleus of the vagus and the NTS, 54 where glucose-sensitive catecholaminergic neurons are located, which project to the hypothalamus, in particular the PVN and the AN. 55, 58 Immunotoxin destruction of these neurons showed their role in the feeding response to the 2-DG glucoprivic signal 56 and in the regulation of NPY and Agrp expression. 55 A role for central Glut2 expression in feeding regulation has been suggested by experiments in which its expression was decreased by the injection of antisense oligonucleotides in the AN. This led to a reduction in feeding and body weight and a suppression of the feeding response to 2-DG. 80 In the Glut2-null (ripglut1;glut2 À/À ) mice ad libitum feeding was B20% higher than in controls, and, after a 24 h fast, they initiated feeding less rapidly than control mice but progressively ate more so that cumulative food intake over 48 h was again higher than that of control mice. 81 The feeding responses to intracerebroventricular glucose or 2-DG was also lost in these mutant mice. In parallel, evaluation of the expression of the orexigenic (NPY, Agrp) and anorexigenic (POMC, CART) neuropeptides during the fast-to-refed transition revealed that, in the absence of Glut2, the normal regulation of the expression of these neuropeptides was suppressed. The latter was a direct consequence of the loss of central glucose sensing, as intracerebroventricular glucose in fasted mice failed to reduce NPY and to increase POMC expression. These data indicate that Glut2 is required for physiological control of feeding by glucose. Attempts at localizing Glut2 in the brain has failed to show its expression in POMC or NPY neurons, although it was found to be associated with other hypothalamic and brainstem structures 63, [82] [83] [84] [85] and expressed by neurons, astrocytes, endothelial cells and tanycytes of the third ventricle. [86] [87] [88] Thus, the regulation of orexigenic and anorexigenic peptide expressions by Glut2-dependent sensors may be controlled indirectly, possibly even by sensors located in other brain regions, such as the brainstem, in possible agreement with the reported presence in this structure of glucose-sensitive neurons that control feeding.
The above observations should also be discussed in the context of studies of mice with POMC or NPY neuronspecific inactivation of genes coding for proteins involved in glucose detection. For instance, a recent study reported that transgenic expression in POMC neurons of a constitutively active Kir6.2 subunit, which generates K ATP channels that can no longer be regulated by glucose, led to complete unresponsiveness of these neurons to elevations in extracellular glucose concentration. 89 The feeding behavior of these mice was however normal, suggesting that glucose sensing by these cells was not critical for the physiological control of feeding. The metabolic sensor AMP-activated kinase, which is activated by low glucose concentrations, may also participate in the control by glucose of feeding through a regulation of the melanocortin pathway. 90 Inactivation of this kinase either in POMC or in NPY/Agrp neurons suppressed the regulation by glucose of their firing activity. 91 However, absence of this enzyme from the POMC neurons led to increased feeding and body weight. As POMC neurons are anorexigenic, AMP kinase, which is activated by low glucose, should be expected to suppress POMC expression to increase feeding. Inactivation of AMP kinase in these cells should therefore lead to increased POMC expression and a leanness phenotype, which is the opposite of what was found. Inactivation of AMP kinase in NPY/Agrp neurons led to a slight leanness phenotype, which developed after 3 months of age. This was not associated with differences in feeding nor in orexigenic and anorexigenic neuropeptide expressions. Thus, these observations suggest that the physiological regulation by glucose of the melanocortin pathway and its role in feeding may be indirect, possibly through Glut2-expressing cells located at other anatomical sites, such as the brainstem. Glucokinase may also participate in the control of feeding. 65, 66 For instance, pharmacological inhibition of glucokinase by intracerebroventricular alloxan injections induced feeding. 92 Thus, as for counter-regulation, the control of feeding by glucose appears to depend on glucose sensing by several sites, which may also be present in the hepatoportal vein region, the brainstem and the hypothalamus. These different sites clearly interact with each other and the control of feeding in physiological conditions may rely mostly on portal and brainstem glucose sensing, signals that are then integrated at the melanocortin pathway.
Glucose-lipid interaction
Glucolipotoxicity and beta-cells Circulating free fatty acids are required for normal glucosestimulated insulin secretion, 93 and incubation of pancreatic islets in the presence of elevated fatty acid concentrations leads to an initial increase in glucose-stimulated insulin secretion. 94 However, after longer periods of times (418 h),
Glucose sensing in metabolic diseases B Thorens free fatty acids reduce the secretory response to glucose. 95 This has been attributed to the accumulation of fatty acylCoAs that can generate various lipid species that interfere with the function of ionic channels or other proteins regulating the exocytosis of insulin granules. 96 Free fatty acids have also been shown to decrease the expression of key components of the glucose signaling pathway, such as Glut2 and glucokinase, through an initial reduction in PDX-1 expression. 97 There is now also evidence that elevated concentrations of free fatty acids may induce ER stress, which may be protective over short periods of times but deleterious if they last too long. 98 Free fatty acids have also been shown to regulate hypothalamic functions, possibly through interacting with the normal use and metabolism of glucose (see Figure 1) . The group of Rossetti and colleagues 99 have provided evidence that intracerebroventricular oleic acid infusion leads to an inhibition of feeding and a decrease in hepatic glucose output. This was proposed to depend on the level of cytoplasmic fatty acyl-CoA, which can be either increased or decreased by reducing the expression of Cpt1, 100 or by activating it by a reduction in malonyl-CoA induced by overexpression of a malonyl-CoA decarboxylase. 101 The effects of fatty acids can be blocked by genetic or pharmacological inhibition of the K ATP channel and are transduced to the liver through vagal innervation. 102, 103 The inhibition of fatty acid synthase by the compound C75 also leads to a decrease in feeding and reduction in body weight in obese mice. 104 This effect was suggested to be secondary to an increase in malonyl-CoA and the consequent inhibition of Cpt1. However, it was also suggested that the cause of reduced food intake after C75 treatment was not the increase in long-chain fatty acyl-CoAs but rather the consequent increase in glucose uptake and metabolism. 105 Figure 1 A model for glucose-lipid metabolic interactions in the control of neuron firing and feeding control. An increase in extracellular glucose leads to increased glucose uptake and metabolism. According to the beta-cell model, glycolysis then generates pyruvate, which enters the mitochondria through the pyruvate dehydrogenase complex (PDH) to feed the Krebs cycle (KC). This is followed by an increase in the ATP/ADP ratio through oxidative phosphorylation, which leads to the closure of K ATP channels. Glucose metabolism also generates citrate, which can be transported to the cytosol to generate acetyl-CoA, that is converted by acetylCoA carboxylase (ACC) into malonyl-CoA, a direct precursor for fatty acids biosynthesis by fatty acid synthase (Fas). Malonyl-CoA also inhibits carnitine palmitoylCoA transferase (Cpt1), thereby reducing b-oxidation rates. The intracellular accumulation of fatty acyl-CoAs may decrease feeding by a regulation of the neuronfiring rate through the regulation of the K ATP channel. The C75 compound reduces feeding by inhibiting Fas, which leads to increased accumulation of malonyl-CoA and thus an intracellular accumulation of fatty acyl CoA. It has also been proposed that the reduction in feeding caused by C75 may be consequent to an increase in glucose utilization when Cpt1 is blocked, rather than consequent to the accumulation of fatty acyl-CoAs. Finally, a decrease in extracellular glucose concentration (left) stimulates feeding through the activation of AMP kinase, which phosphorylates and inactivates ACC, thus reducing malonyl-CoA formation and increasing b-oxidation (see text for further description).
Glucose sensing in metabolic diseases B Thorens S67 low glucose levels, this enzyme is activated and inhibits, by phosphorylation, acetyl-CoA carboxylase. This leads to decreased malonyl-CoA levels, increased b-oxidation and increased feeding. 106 Central lipid sensing also controls insulin secretion. For instance, an intracerebroventricular injection of lipids leads to a rapid increase in insulin secretion during a glucose tolerance test and a reduced suppression of hepatic glucose output. 107 These effects require hypothalamic b-oxidation, and the effect on insulin secretion is secondary to a reduced parasympathetic tone at the level of the beta-cells. 108 Thus, lipids in the central nervous system deregulate autonomic nervous activity, leading to impaired glucose homeostasis. Further evidence for a direct functional interaction of lipid and glucose on AN neurons has been provided by measuring their firing rate after exposure to oleic acid, and in the presence of different glucose concentrations. 109 These studies clearly show that the effect of the fatty acid could increase or decrease the firing rate of different neuron subpopulations and that these effects could be modulated by changes in extracellular glucose concentrations.
Conclusions
Circulating glucose concentrations can be monitored by multiple systems located at different anatomical sites. These control insulin secretion by pancreatic beta-cells by a signaling pathway that has been well described, which requires glucose metabolism to control plasma membrane electrical activity. Evidence has been gained that other glucose-sensing systems exist in the hepatoportal vein region, the brainstem and the hypothalamus to control counter-regulation, feeding behavior and the cephalic phase, as well as the first phase of insulin secretion. There is evidence that there is more than one mechanism to sense either an increase or a decrease in glycemia level, and that the beta-cell model of glucose sensing may have many variations. For instance, the portal vein glucose sensor can be activated by pyruvate and lactate, signals that must be excluded from those stimulating insulin secretion by betacells, as they would induce hypoglycemia in the fasted state. GI neurons respond to glucose by mechanisms that apparently do not involve the K ATP channel but rather a regulation of the Na/K ATPase. Control of glucagon secretion by the autonomic nervous system may require Glut2 expression in astrocytes for the nervous control of alpha-cell secretion, suggesting that glucose sensing requires metabolic coupling between astrocytes and neurons. Therefore, the brain, which critically depends on glucose for its function, has evolved many glucose-sensing systems to fine-tune glucose homeostasis through the regulation of glucagons and insulin secretion, and through the regulation of feeding behavior and energy homeostasis. However, these glucose-sensing systems also integrate other signals such as those provided by leptin, ghrelin or insulin, but also from other nutrients such as lipids, as discussed here. It is striking that peripheral and central glucose sensors control physiological functions, which, when deregulated, trigger early signs of the pathogenesis of obesity and diabetes, such as abnormal suppression of glucagon secretion in the fed state, loss of first-phase insulin secretion, impaired termination of feeding and decreased peripheral tissue glucose uptake. These deregulations become evident before full impairment of beta-cell secretion appears, a characteristic of established type 2 diabetes. Thus, deregulation of these extrapancreatic glucose sensors, possibly due to lipidinduced dysfunction, may be early events in the pathogenesis of obesity and type 2 diabetes.
